APT (weekly paclitaxel + trastuzumab)
Checked 2026-09-09
Stage I HER2-positive breast cancer, node-negative, tumour 3 cm or smaller
One cycle
weekly × 12 · about 12 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Paclitaxel Cytotoxic chemotherapy (taxane) | 80 mg/m² | IV | D1 | |
Trastuzumab Monoclonal antibody (anti-HER2) | 4 mg/kg loading then 2 mg/kg weekly; 6 mg/kg every 3 weeks after chemotherapy | IV | D1 |
Cycles
12 weekly, then trastuzumab every 3 weeks to 1 year
7-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Not routine
Notes
- 7-year disease-free survival 93%; T-DM1 × 17 (ATEMPT) is the alternative.
Used in
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Dose-dense AC → T
Node-positive or high-risk early breast cancer, adjuvant or neoadjuvant
every 14 days × 4
TCHP
Stage II-III HER2-positive breast cancer, neoadjuvant
every 21 days × 6
THP (docetaxel + trastuzumab + pertuzumab)
HER2-positive metastatic breast cancer first line, then HP maintenance
every 21 days
Trastuzumab deruxtecan 5.4 mg/kg
HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC
every 21 days